NCT05734807 - A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

April 17, 2024

Study Completion Date

April 17, 2024

Conditions

Chronic HBV Infection

Interventions

DRUG

Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)

Subjects will receive NrtIs therapy for 24 weeks.

DRUG

HH-003 and NrtIs

Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.

DRUG

HH-003, NrtIs and PEG-IFN-α

Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.

Trial Locations (8)

Beijing Ditan Hospital,Capital Medical University, Beijing

Beijing Friendship Hospital,Capital Medical University, Beijing

Beijing Youan Hospital,Capital Medical University, Beijing

The First Hospital of Jilin University, Changchun

Shandong Public Health Clinical Center, Jinan

Mengchao Hepatobiliary Hospital Of Fujian Medical University, Fuzhou

The Sixth Peoples Hospital Of Zhengzhou, Zhengzhou

Nanfang Hospital of Southern Medical University, Guangzhou